Interviews

Joseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.

Bishoy M. Faltas, MD, discusses the significance of studying the response of tumor tissue to mutation-targeted agents in urothelial cancer.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

John Mascarenhas, MD, provides advice to oncologists on the use of pacritinib to treatment patients with myelofibrosis and severe thrombocytopenia.

John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.

Solange Peters, MD, PhD, discusses the design of the CheckMate743 study of doublet immunotherapy for patients with malignant pleural mesothelioma.

Jorge Nieva, MD, explains how international drug developers should approach the approval application process after a biologics license application for sintilimab plus chemotherapy for the treatment of nonsquamous non–small cell lung cancer was not successful.

Ronald L. Paquette, MD, discusses characteristics of myelodysplastic syndrome and how they may impact a patient’s success in undergoing stem cell transplant.

Sumanta K. Pal, MD, explains what gastrointestinal cancer research needs to focus on in the near future.

David W. Dougherty, MD, discusses how cancer centers can move forward following the negative effects caused by the COVID-19 pandemic.

Lori A. Leslie, MD, discusses her recent presentation around chimeric antigen receptor T-cell therapy for mantle cell lymphoma and indolent lymphomas.

Thomas Powles, MD, MBBS, MRCP, discusses the implications of the positive outcome of the phase 3 EV-301 trial of enfortumab vedotin in patients with urothelial cancers.

Jorge Nieva, MD, discusses how a future clinical trial of sintilimab injection plus chemotherapy should look in order to achieve FDA approval for the treatment of patients with nonsquamous non–small cell lung cancer.

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.

William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.

Jorge Nieva, MD, discusses why he voted differently from the other members of the FDA’s Oncologic Drug Advisory Committee regarding sintilimab in combination with chemotherapy for the first-line treatment of patients with nonsquamous non–small cell lung cancer.

Jorge Nieva, MD, discusses what’s needed for frontline sintilimab plus chemotherapy to have a future in United States patients with nonsquamous non–small cell lung cancer after a negative ODAC vote.

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

Jennifer R. Brown, MD, PhD, discusses the patient population of the SEQUOIA trial of zanubrutinib and venetoclax for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Toufic Kachaamy, MD, discusses an upcoming course that teaches the multidisciplinary approach for clinicians who have a hand in treating gastrointestinal cancers.

Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.

Ronald S. Go, MD, explains how toxicities of treatment for histiocytic neoplasms compared with toxicities observed in other malignancies.

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

Bhavana Pothuri, MD, discusses the results of the KEYNOTE-775 trial in patients with advanced endometrial cancer in relation to microsatellite instability status.

Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma

Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

According to Bradley J. Monk, MD, FACOG, FACS, cemiplimab achieved better response and a longer overall survival compared with chemotherapy in patients with cervical cancer.